Engineered silybin nanoparticles educe efficient control in experimental diabetes

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Das, Suvadra ^a   Roy, Partha ^a,b   Pal, Rajat ^a   Auddy, Runa Ghosh ^a   Chakraborti, Abhay Sankar ^a   Mukherjee, Arup ^a  

^a UNIVERSITY OF CALCUTTA   (India)

^b UNIVERSITY MALAYSIA PAHANG   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CATALASE; CHITOSAN; CHOLESTEROL; FRUCTOSAMINE; GLUCOSE; GLUTATHIONE; GLYCOGEN; HEMOGLOBIN A1C; INSULIN; MALONALDEHYDE; NANOPARTICLE; SILIBININ; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; BIOMATERIAL; GLUCOSE BLOOD LEVEL; SILYMARIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DIFFUSION; DRUG SOLUBILITY; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOGEN LIVER LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; NANODEVICE; NANOENCAPSULATION; NONHUMAN; PASSIVE TRANSPORT; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ZETA POTENTIAL; ANIMAL; BLOOD; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; HUMAN; LIVER; METABOLISM; PARTICLE SIZE; WISTAR RAT;

ANIMALS; BIOCOMPATIBLE MATERIALS; BLOOD GLUCOSE; CHITOSAN; DIABETES MELLITUS, EXPERIMENTAL; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SILYMARIN; STREPTOZOCIN;

EID: 84903777316     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101818     Document Type: Article

References (71)

1. World Health Organization (2013) Diabetes. Geneva: WHO. Available: www.who.int/mediacentre/factsheets/fs312/en/?. Accessed 2014 March 24.
2. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
3. Murali R, Srinivasan S, Ashokkumar N (2013) Antihyperglycemic effect of fraxetin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-induced diabetic rats. Biochimie 95: 1848-1854.
4. McAnuff MA, Omoruyi FO, Morrison EY, Asemota HN (2005) Changes in some liver enzymes in streptozotocin-induced diabetic rats fed sapogenin extract from bitter yam (Dioscorea polygonoides) or commercial diosgenin. West Indian Med J 54: 97-101. (Pubitemid 40873134)
5. Hii CS, Howell SL (1985) Effects of flavonoids on insulin secretion and 45Ca2+ handling in rat islets of langerhans. J Endocrinol 107: 1-8. (Pubitemid 16247388)
6. Vessal M, Hemmati M, Vasei M (2003) Antidiabetic effects of quercetin in streptozocin induced diabetic rats. Comp Biochem Physiol C 135: 357-364. (Pubitemid 36962949)
7. Nielsen SE, Breinholt V, Justesen U, Cornett C, Dragsted LO (1998) In vitro biotransformation of flavonoids by rat liver microsomes. Xenobiotica 28: 389-401. (Pubitemid 28207043)
8. Piskula MK, Terao J (1998) Accumulation of (-)-epicatechin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues. J Nutr 128: 1172-1178. (Pubitemid 28317683)
9. Barwal I, Sood A, Sharma M, Singh B, Yadav SC (2013) Develpoment of stevioside Pluronic-F- 68 copolymer based PLAnanoparticles as an antidiabetic nanomedcine. Colloids Surf B Biointerfaces 101: 510-516.
10. Hoh CS, Boocock DJ, Marczylo TH, Brown VA, Cai H, et al. (2007) Quantitation of Silibinin, a Putative Cancer Chemopreventive Agent Derived from Milk Thistle (Silybum marianum), in Human Plasma by High-Performance Liquid Chromatography and Identification of Possible Metabolites. J Agric Food Chem 55: 2532-2535. (Pubitemid 46623745)
11. Kvasnicka F, Biba B, Sevcik R, Voldrich M, Kratka J (2003) Analysis of the active components of silymarin. J Chromatogr A 990: 239-245. (Pubitemid 36293880)
12. Saller R, Meier R, Brignoli R (2001) The use of silymarin in the treatment of liver diseases. Drugs 61: 2035-2063. (Pubitemid 33135182)
13. Zi X, Agarwal R (1999) Silibinin decreases prostate- specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. PNAS 96: 7490-7495. (Pubitemid 29299689)
14. Saliou C, Rihn B, Cillard J, Okamoto T, Packer L (1998) Selective inhibition of NF-kappa-B activation by the flavonoid hepatoprotector silymarin in HepG2: Evidence for different activating pathways. FEBS Lett 440: 8-12. (Pubitemid 28558724)
15. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, et al. (1997) Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 26: 871-879. (Pubitemid 27145712)
16. Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, et al. (2002) Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr Metab 15: 222-231. (Pubitemid 35189806)
17. Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, et al. (2006) The efficacy of silybum marianum (L.) Gaertn. (Silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 20: 1036-1039. (Pubitemid 44951705)
18. Maghrani M, Zeggwagh NA, Lemhadri A, El Amraoui M, Michel JB, et al. (2004) Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes mellitus. J Ethnopharmacol 91: 309-316. (Pubitemid 38561128)
19. Soto CP, Perez BL, Favari LP, Reyes JL (1998) Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 119: 125-129. (Pubitemid 28221648)
20. Guigas B, Naboulsi R, Villanueva GR, Taleux N, Lopez-Novoa JM, et al. (2007) The Flavonoid Silibinin Decreases Glucose-6- Phosphate Hydrolysis in Perifused Rat Hepatocytes by an Inhibitory Effect on Glucose-6-Phosphatase. Cell Physiol Biochem 20: 925-934. (Pubitemid 350059735)
21. Malekinejad H, Rezabakhsh A, Rahmani F, Hobbenaghi R (2012) Silymarin regulates the cytochrome P450 3A2 and glutathione peroxides in the liver of streptozotocin-induced diabetic rats. Phytomedicine 19: 583-590.
22. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly (D,L-lactide-co-glycolide) and its derivatives. J Control Release 125: 193-209.
23. Roy P, Das S, Auddy RG, Saha A, Mukherjee A (2013) Engineered andrographolide nanoparticles mitigate paracetamol hepatotoxicity in mice. Pharm Res 30: 1252-1262.
24. Das S, Roy P, Islam A, Saha A, Mukherjee A (2013) Poly (DL-lactide-co-glycolic acid) nanoparticle design and payload prediction: a molecular descriptor based study. Chem Pharm Bull 61: 125-133.
25. Fallouh NAK, Roblot-Treupel L, Fessi H, Devissaguet JP, Puisieux F (1986) Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int J Pharm 28: 125-132. (Pubitemid 16187088)
26. Fessi H, Puisieux P, Devissaguet JP, Ammoury N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Intl J Pharm 55: R1-R4. (Pubitemid 19247505)
27. Pillai SI, Subramanian SP, Kandaswamy M (2013) A novel insulin mimetic vanadium-flavonol complex: synthesis, characterization and in vivo evaluation in STZ-induced rats. Eur J Med Chem 63: 109-117.
28. Zhuang J, Ping Q, Song Y, Qi J, Cui Z (2010) Effects of chitosan coating on physical properties and pharmacokinetic behavior of mitoxantrone liposomes. Int J Nanomed 5: 407-416.
29. Shivanna N, Naika M, Khanum F, Kaul VK (2013) Antioxidant, anti-diabetic and renal protective properties of Stevia rebaudiana. J Diabetes Complications 27: 103-113.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
31. Johnson RN, Metcalf PA, Baker JR (1983) Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta 127: 87-95. (Pubitemid 13168108)
32. Jariyapamornkoon N, Yibchok-anun S, Adisakwattana S (2013) Inhibition of advanced glycation end products by red grape skin extract and its antioxidant activity. BMC Complement Altern Med 13: 171.
33. Yagi K (1987) Lipid peroxides and human diseases. Chem Phys Lipids 45: 337-351.
34. Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47: 469-474.
35. Aebi H (1984) Catalase in vitro. Methods Enzymol 105: 121-126.
36. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70-77.
37. Murat JC, Serfaty A (1974) Simple enzymatic determination of polysaccharide (glycogen) content of animal tissues. Clin Chem 20: 1576-1577.
38. Liu SH, Chang YH, Chiang MT (2010) Chitosan reduces gluconeogenesis and increases glucose uptake in skeletal muscle in streptozotocin-induced diabetic rats. J Agric Food Chem 58: 5795-5800.
39. Vialettes B, Vovan L, Simon MC, Lassmann V, Altomare E, et al. (1982) Kinetics of fast haemoglobin in diabetic rats. Diabetologia 22: 264-268. (Pubitemid 12140953)
40. Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM (1986) Glycated hemoglobin: methodologies and clinical applications. Clin Chem 32: B64-B70.
41. Bhattacharyya J, Bhattacharyya M, Chakraborti AS, Chaudhuri U, Poddar RK (1998) Structural organisations of hemoglobin and myoglobin influence their binding behaviour with phenothiazines. Int J Biol Macromol 23: 11-18. (Pubitemid 28282513)
42. Wu JT, Tu MC, Zhung P (1996) Advanced glycation end product (AGE): characterization of the products from the reaction between D-glucose and serum albumin. J Clin Lab Anal 10: 21-34. (Pubitemid 26049785)
43. Merisko-Liversidge EM, Liversidge GG (2008) Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 36: 43-48.
44. Liu VA, Jastromb WE, Bhatia SN (2001) Engineering protein and cell adhesivity using PEO-terminated triblock polymers. J Biomed Mater Res 60: 126-134. (Pubitemid 34126994)
45. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC (2010) Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 351: 19-29.
46. Bellamy LJ (1975) The infrared spectra of complex molecules. London UK: Chapman and Hall. 107-128.
47. Yan S, Zhu J, Wang Z, Yin J, Zheng Y, et al. (2011) Layer-by-layer assembly of poly (L-glutamic acid)/chitosan microcapsules for high loading and sustained release of 5-fluorouracil. Eur J Pharm Biopharm 78: 336-345.
48. Budhian A, Siegel SJ, Winey KI (2008) Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm 346: 151-159. (Pubitemid 350101995)
49. Zhuang J, Ping Q, Song Y, Qi J, Cui Z (2010) Effects of chitosan coating on physical properties and pharmacokinetic behavior of mitoxantrone liposomes. Int J Nanomed 5: 407-416.
50. Wang Q, Liu M, Liu WW, Hao WB, Tashiro S, et al. (2012) In vivo recovery effect of silibinin treatment on streptozotocin-induced diabetic mice is associated with the modulations of Sirt-1 expression and autophagy in pancreatic β-cell. J Asian Nat Prod Res 14: 413-423.
51. Pradeep K, Mohan CV, Gobianand K, Karthikeyan S (2007) Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. Eur J Pharmacol 560: 110-116. (Pubitemid 46341309)
52. Sozmen EY, Sozmen B, Delen Y, Onat T (2001) Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control. Arch Med Res 32: 283-287. (Pubitemid 32611640)
53. Yan H, Harding JJ (1997) Glycation-induced inactivation and loss of antigenicity of catalase and superoxide dismutase. Biochem J 328: 599-603.
54. Loven D, Schedl H, Wilson H, Daabees TT, Stegink LD, et al. (1986) Effect of insulin and oral glutathione on glutathione levels and superoxide dismutase activities in organs of rats with streptozocin-induced diabetes. Diabetes 35: 503-507. (Pubitemid 16085320)
55. Soto C, Pérez J, García V, Uría E, Vadillo M, et al. (2010) Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine 17: 1090-1094.
56. Soto C, Mena R, Luna J, Cerbon M, Larrieta E, et al. (2004) Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci 75: 2167-2180. (Pubitemid 39120024)
57. Sersen F, Vencel T, Annus J (2006) Silymarin and its components scavenge phenylglyoxylic ketyl radicals. Fitoterapia 77: 525-529. (Pubitemid 44738270)
58. Armbruster DA (1987) Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 33: 2153-2163.
59. Cohen MP, Wu VY (1994) Purification of glycated hemoglobin. Methods Enzymol. 231: 65-75.
60. Tjälve H, Wilander E, Johansson EB (1976) Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets. J Endocrinol 69: 455-456.
61. Bennett RA, Pegg AE (1981) Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res 41: 2786-2790.
62. Konrad RJ, Kudlow JE (2002) The role of O-linked protein glycosylation in beta-cell dysfunction. Int J Mol Med 10: 535-539.
63. Uchigata Y, Yamamoto H, Kawamura A, Okamoto H (1982) Protection by superoxide dismutase, catalase, and poly (ADPribose) synthetase inhibitors against alloxan- and streptozotocininduced islet DNA strand breaks and against the inhibition of proinsulin synthesis. J Biol Chem 257: 6084-6088. (Pubitemid 12029522)
64. Nukatsuka M, Yoshimura Y, Nishida M, Kawada J (1990) Allopurinol protects pancreatic beta cells from the cytotoxic effect of streptozotocin: in vitro study. J Pharmacobiodyn 13: 259-262. (Pubitemid 20195764)
65. Strandell E, Eizirik DL, Korsgren O, Sandler S (1988) Functional characteristics of cultured mouse pancreatic islets following exposure to different streptozotocin concentrations. Mol Cell Endocrinol 59: 83-91.
66. King GL, Loeken MR (2004) Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 122: 333-338. (Pubitemid 39506591)
67. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, et al. (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49: 1939-1945.
68. Bertelsen M, Anggard EE, Carrier MJ (2001) Oxidative stress impairs insulin internalization in endothelial cells in vitro. Diabetologia 44: 605-613. (Pubitemid 32411277)
69. Vengerovskii AI, Khazanov VA, Eskina KA, Vasilyev KY (2007) Effects of silymarin (hepatoprotector) and succinic acid (bioenergy regulator) on metabolic disorders in experimental diabetes mellitus. Bull Exp Biol Med 144: 58-61.
70. Kajimoto Y, Kaneto H (2004) Role of oxidative stress in pancreatic beta-cell dysfunction. Ann N Y Acad Sci 1011: 168-176. (Pubitemid 38608402)
71. Li L, Wang H, Ong ZY, Xu K, Rachel Ee PL, et al. (2010) Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today 5: 296-312.